Oral vs. Injectable GLP-1: Rybelsus, the Lilly Pill, and Tracking Differences

The oral GLP-1 wave is here

For the first eight years of the GLP-1 era, every clinically relevant GLP-1 agonist was an injection. That changed with Rybelsus (oral semaglutide), approved in 2019, and is changing further as Eli Lilly and others bring oral GLP-1 / dual-agonist formulations toward mainstream availability. The injection-only landscape is becoming injection-or-oral.

For tracking, this matters: oral and injectable GLP-1s have different dosing schedules, different bioavailability, different food restrictions, and different protocol shapes. A user switching from injection to oral isn't just changing the delivery mechanism — they're changing the entire protocol structure.

Oral semaglutide (Rybelsus): how it works

Rybelsus is the same active molecule as Ozempic/Wegovy (semaglutide), formulated with an absorption enhancer (SNAC — sodium N-(8-(2-hydroxybenzoyl)amino)caprylate) that allows the peptide to survive gastric pH and cross the gut epithelium. Without SNAC, semaglutide would be digested before absorption.

Even with SNAC, oral bioavailability is approximately 0.4–1% — meaning ~99% of the dose doesn't reach systemic circulation. This is why oral semaglutide doses (3 mg, 7 mg, 14 mg daily) are much higher than injectable (0.25–2.4 mg weekly): the injected version is far more bioavailable.

Oral vs. injection comparison

The fasted-dosing requirement is non-trivial

Oral semaglutide must be taken on an empty stomach, with no more than 4 oz (120 mL) of plain water, at least 30 minutes before eating, drinking anything else, or taking other oral medications. This window is rigid — eating or drinking too soon after dosing significantly reduces absorption.

For users coming from weekly injection (no food/timing constraints), this is a meaningful change in daily life. The "5 minutes a week" of injectable becomes "30 minutes every morning" of constraint with oral.

Tirzepatide oral formulations: not yet

As of early 2026, tirzepatide is still injection-only (Mounjaro/Zepbound). Lilly has a daily oral formulation in late-stage development (orforglipron is a separate oral GLP-1 candidate from Lilly, not oral tirzepatide). Expect this space to evolve rapidly.

What tracking changes when you go from injection to oral

Common tracking shifts:

• From weekly to daily: Injection users log 1 dose/week; oral users log 7 doses/week. The log becomes more granular.
• No reconstitution math: Oral tablets eliminate the recon calculator step. The bac water + units math goes away.
• No site rotation: Oral eliminates injection site tracking entirely.
• Compliance window matters more: A daily 30-minute fasted window is harder to maintain than a weekly injection. Tracking "did I take it correctly?" (not just "did I take it?") becomes the relevant question.
• Half-life unchanged: Same active molecule, same ~7-day half-life means the half-life chart still applies. Steady-state and washout windows are the same.

Cost differences

Injection-form GLP-1s, especially compounded versions, are typically cheaper per month than brand-name oral GLP-1s. As of 2026:

• Compounded injectable semaglutide: ~$200–400/month (varies by pharmacy)
• Brand-name Ozempic/Wegovy with insurance: highly variable, $0–$1,300/month
• Brand-name Rybelsus: ~$900–$1,000/month list price
• Future oral GLP-1s (Lilly's pipeline): announced targets near $149/month to compete with compounded injectables

Cost dynamics will shift dramatically as oral formulations mature and compounding access changes. Today's pricing landscape is not stable.

Should you switch from injection to oral?

Whether to switch is a clinical decision for your prescribing provider based on:

• FDA-approved indication for your condition (Rybelsus for diabetes only as of 2026; not approved for obesity)
• Your tolerance for daily fasted dosing vs. weekly injection
• Your ability to reliably maintain the 30-minute fasted window
• Insurance coverage and out-of-pocket cost
• Whether you've reached your therapeutic dose level (escalation is slower with oral)

Some users find oral easier to maintain long-term. Others find weekly injection lower-friction overall. There's no universally correct answer.

Tracking either format

My Pep Calc supports both injection and oral protocols. For injection: dose log with reconstitution math, site rotation, weekly cadence. For oral: daily compliance log with fasted-window tracking. The half-life chart works for both since active concentration is the same regardless of delivery mechanism.

If you switch mid-protocol, the log captures both phases — useful for clinical review of which format produced better outcomes for you specifically.